CompletedPhase 2NCT04385719
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Makerere University
- Principal Investigator
- Mohammed J Lamorde, PhDInfectious Diseases Institute, Uganda
- Intervention
- Remdesivir(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2021 – 2021
Study locations (1)
- Infectious Diseases Institute, Kampala, Uganda
Collaborators
University of Liverpool · European and Developing Countries Clinical Trials Partnership (EDCTP) · University of Turin, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04385719 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University